Literature DB >> 29228077

Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little?

Vinay Prasad1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29228077     DOI： 10.1001/jamapediatrics.2017.4360

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN： 2168-6203            Impact factor:   16.193


× No keyword cloud information.
  5 in total

1.  Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy.

Authors:  Ali Jalali; Erin Rothwell; Jeffrey R Botkin; Rebecca A Anderson; Russell J Butterfield; Richard E Nelson
Journal:  J Pediatr       Date:  2020-07-11       Impact factor: 4.406

Review 2.  Recent advances in understanding congenital myopathies.

Authors:  Gianina Ravenscroft; Robert J Bryson-Richardson; Kristen J Nowak; Nigel G Laing
Journal:  F1000Res       Date:  2018-12-11

Review 3.  Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.

Authors:  Alessandra Blonda; Teresa Barcina Lacosta; Mondher Toumi; Steven Simoens
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

4.  The prevalence of muscular dystrophy and spinal muscular atrophy in Croatia: data from national and non-governmental organization registries.

Authors:  Željka Draušnik; Ivan Cerovečki; Vesna Štefančić; Sandra Mihel; Ranko Stevanović; Nina Barišić; Hana Matković; Matea Melša; Marica Mirić; Neda Pjevač; Tomislav Benjak
Journal:  Croat Med J       Date:  2019-12-31       Impact factor: 1.351

Review 5.  Advances in oligonucleotide drug delivery.

Authors:  Thomas C Roberts; Robert Langer; Matthew J A Wood
Journal:  Nat Rev Drug Discov       Date:  2020-08-11       Impact factor: 84.694
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.